Rohto Pharmaceutical Publishes 2026 Annual Report

Bitget2026/10/30 02:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rohto Pharmaceutical published its 2026 integrated annual report, reporting record sales and operating profit for fiscal 2025.
Growth in Southeast Asia and contributions from Eu Yan Sang and MoNo supported overseas expansion.
The group expects to reach its fiscal 2027 sales target in fiscal 2026, one year ahead of schedule.
Medical operations remain a growth investment priority, with partnerships advancing regenerative medicine commercialization and contract manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rohto Pharmaceutical Publishes 2026 Annual Report

You may also like

Crypto prices